Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease: Intermediate Term Follow-up

Tadahisa Sugiura, Goki Matsumura, Shinka Miyamoto, Hideki Miyachi, Christopher K. Breuer, Toshiharu Shinoka

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Tissue engineering holds great promise for the advancement of cardiovascular surgery as well as other medical fields. Tissue-engineered vascular grafts have the ability to grow and remodel and could therefore make great advances for pediatric cardiovascular surgery. In 2001, we began a human clinical trial evaluating these grafts in patients with a univentricular physiology. Herein, we report the long-term results of patients who underwent implantation of tissue-engineered vascular grafts as extracardiac total cavopulmonary conduits. Tissue-engineered vascular grafts seeded with autologous bone marrow mononuclear cells were implanted in 25 patients with univentricular physiology. The graft is composed of a woven fabric of poly-l-lactide acid or polyglycolic acid and a 50:50 poly (l-lactic-co-ε-caprolactone) copolymer. Patients were followed up with postoperatively in a multidisciplinary clinic. Median patient age at operation was 5.5 years and the mean follow-up period was 11.1 years. There was no graft-related mortality during the follow-up period. There was also no evidence of aneurysmal formation, graft rupture, graft infection, or calcification. Seven (28%) patients had asymptomatic graft stenosis and underwent successful balloon angioplasty. Stenosis is the primary complication of the tissue-engineered vascular graft. Avoidance of anticoagulation therapy would improve patients’ quality of life. Tissue-engineered vascular grafts have feasibility in pediatric cardiovascular surgery.

Original languageEnglish (US)
Pages (from-to)175-179
Number of pages5
JournalSeminars in Thoracic and Cardiovascular Surgery
Volume30
Issue number2
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Blood Vessel Prosthesis
Heart Diseases
Transplants
Pathologic Constriction
Pediatrics
Polyglycolic Acid
Balloon Angioplasty
Tissue Engineering
Bone Marrow Cells
Rupture
Milk
Quality of Life
Clinical Trials
Acids
Mortality
Infection

Keywords

  • congenital heart disease
  • Fontan surgery
  • pediatric cardiac surgery
  • tissue-engineering
  • univentricular physiology

ASJC Scopus subject areas

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease : Intermediate Term Follow-up. / Sugiura, Tadahisa; Matsumura, Goki; Miyamoto, Shinka; Miyachi, Hideki; Breuer, Christopher K.; Shinoka, Toshiharu.

In: Seminars in Thoracic and Cardiovascular Surgery, Vol. 30, No. 2, 01.06.2018, p. 175-179.

Research output: Contribution to journalArticle

Sugiura, Tadahisa ; Matsumura, Goki ; Miyamoto, Shinka ; Miyachi, Hideki ; Breuer, Christopher K. ; Shinoka, Toshiharu. / Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease : Intermediate Term Follow-up. In: Seminars in Thoracic and Cardiovascular Surgery. 2018 ; Vol. 30, No. 2. pp. 175-179.
@article{88104e84d19d4c1792dc2e4f22277574,
title = "Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease: Intermediate Term Follow-up",
abstract = "Tissue engineering holds great promise for the advancement of cardiovascular surgery as well as other medical fields. Tissue-engineered vascular grafts have the ability to grow and remodel and could therefore make great advances for pediatric cardiovascular surgery. In 2001, we began a human clinical trial evaluating these grafts in patients with a univentricular physiology. Herein, we report the long-term results of patients who underwent implantation of tissue-engineered vascular grafts as extracardiac total cavopulmonary conduits. Tissue-engineered vascular grafts seeded with autologous bone marrow mononuclear cells were implanted in 25 patients with univentricular physiology. The graft is composed of a woven fabric of poly-l-lactide acid or polyglycolic acid and a 50:50 poly (l-lactic-co-ε-caprolactone) copolymer. Patients were followed up with postoperatively in a multidisciplinary clinic. Median patient age at operation was 5.5 years and the mean follow-up period was 11.1 years. There was no graft-related mortality during the follow-up period. There was also no evidence of aneurysmal formation, graft rupture, graft infection, or calcification. Seven (28{\%}) patients had asymptomatic graft stenosis and underwent successful balloon angioplasty. Stenosis is the primary complication of the tissue-engineered vascular graft. Avoidance of anticoagulation therapy would improve patients’ quality of life. Tissue-engineered vascular grafts have feasibility in pediatric cardiovascular surgery.",
keywords = "congenital heart disease, Fontan surgery, pediatric cardiac surgery, tissue-engineering, univentricular physiology",
author = "Tadahisa Sugiura and Goki Matsumura and Shinka Miyamoto and Hideki Miyachi and Breuer, {Christopher K.} and Toshiharu Shinoka",
year = "2018",
month = "6",
day = "1",
doi = "10.1053/j.semtcvs.2018.02.002",
language = "English (US)",
volume = "30",
pages = "175--179",
journal = "Seminars in Thoracic and Cardiovascular Surgery",
issn = "1043-0679",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease

T2 - Intermediate Term Follow-up

AU - Sugiura, Tadahisa

AU - Matsumura, Goki

AU - Miyamoto, Shinka

AU - Miyachi, Hideki

AU - Breuer, Christopher K.

AU - Shinoka, Toshiharu

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Tissue engineering holds great promise for the advancement of cardiovascular surgery as well as other medical fields. Tissue-engineered vascular grafts have the ability to grow and remodel and could therefore make great advances for pediatric cardiovascular surgery. In 2001, we began a human clinical trial evaluating these grafts in patients with a univentricular physiology. Herein, we report the long-term results of patients who underwent implantation of tissue-engineered vascular grafts as extracardiac total cavopulmonary conduits. Tissue-engineered vascular grafts seeded with autologous bone marrow mononuclear cells were implanted in 25 patients with univentricular physiology. The graft is composed of a woven fabric of poly-l-lactide acid or polyglycolic acid and a 50:50 poly (l-lactic-co-ε-caprolactone) copolymer. Patients were followed up with postoperatively in a multidisciplinary clinic. Median patient age at operation was 5.5 years and the mean follow-up period was 11.1 years. There was no graft-related mortality during the follow-up period. There was also no evidence of aneurysmal formation, graft rupture, graft infection, or calcification. Seven (28%) patients had asymptomatic graft stenosis and underwent successful balloon angioplasty. Stenosis is the primary complication of the tissue-engineered vascular graft. Avoidance of anticoagulation therapy would improve patients’ quality of life. Tissue-engineered vascular grafts have feasibility in pediatric cardiovascular surgery.

AB - Tissue engineering holds great promise for the advancement of cardiovascular surgery as well as other medical fields. Tissue-engineered vascular grafts have the ability to grow and remodel and could therefore make great advances for pediatric cardiovascular surgery. In 2001, we began a human clinical trial evaluating these grafts in patients with a univentricular physiology. Herein, we report the long-term results of patients who underwent implantation of tissue-engineered vascular grafts as extracardiac total cavopulmonary conduits. Tissue-engineered vascular grafts seeded with autologous bone marrow mononuclear cells were implanted in 25 patients with univentricular physiology. The graft is composed of a woven fabric of poly-l-lactide acid or polyglycolic acid and a 50:50 poly (l-lactic-co-ε-caprolactone) copolymer. Patients were followed up with postoperatively in a multidisciplinary clinic. Median patient age at operation was 5.5 years and the mean follow-up period was 11.1 years. There was no graft-related mortality during the follow-up period. There was also no evidence of aneurysmal formation, graft rupture, graft infection, or calcification. Seven (28%) patients had asymptomatic graft stenosis and underwent successful balloon angioplasty. Stenosis is the primary complication of the tissue-engineered vascular graft. Avoidance of anticoagulation therapy would improve patients’ quality of life. Tissue-engineered vascular grafts have feasibility in pediatric cardiovascular surgery.

KW - congenital heart disease

KW - Fontan surgery

KW - pediatric cardiac surgery

KW - tissue-engineering

KW - univentricular physiology

UR - http://www.scopus.com/inward/record.url?scp=85044273633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044273633&partnerID=8YFLogxK

U2 - 10.1053/j.semtcvs.2018.02.002

DO - 10.1053/j.semtcvs.2018.02.002

M3 - Article

C2 - 29427773

AN - SCOPUS:85044273633

VL - 30

SP - 175

EP - 179

JO - Seminars in Thoracic and Cardiovascular Surgery

JF - Seminars in Thoracic and Cardiovascular Surgery

SN - 1043-0679

IS - 2

ER -